These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

146 related articles for article (PubMed ID: 30038724)

  • 1. Correction: Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
    Chen R; Li Y; Buttyan R; Dong X
    Oncotarget; 2018 Jul; 9(51):29842. PubMed ID: 30038724
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implications of PI3K/AKT inhibition on REST protein stability and neuroendocrine phenotype acquisition in prostate cancer cells.
    Chen R; Li Y; Buttyan R; Dong X
    Oncotarget; 2017 Oct; 8(49):84863-84876. PubMed ID: 29156689
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correction: CLCA4 inhibits bladder cancer cell proliferation, migration, and invasion by suppressing the PI3K/AKT pathway.
    Hou T; Zhou L; Wang L; Kazobinka G; Zhang X; Chen Z
    Oncotarget; 2019 Jan; 10(9):1010. PubMed ID: 30847028
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Correction: TROP2 promotes proliferation, migration and metastasis of gallbladder cancer cells by regulating PI3K/AKT pathway and inducing EMT.
    Li X; Teng S; Zhang Y; Zhang W; Zhang X; Xu K; Yao H; Yao J; Wang H; Liang X; Hu Z
    Oncotarget; 2019 Nov; 10(60):6540. PubMed ID: 31741718
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Correction: Mechanosensitive caveolin-1 activation-induced PI3K/Akt/mTOR signaling pathway promotes breast cancer motility, invadopodia formation and metastasis
    Yang H; Guan L; Li S; Jiang Y; Xiong N; Li L; Wu C; Zeng H; Liu Y
    Oncotarget; 2018 Aug; 9(66):32730. PubMed ID: 30220978
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Correction: Analysis of miRNA profiles identified miR-196a as a crucial mediator of aberrant PI3K/AKT signaling in lung cancer cells.
    Guerriero I; D'Angelo D; Pallante P; Santos M; Scrima M; Malanga D; De Marco C; Ravo M; Weisz A; Laudanna C; Ceccarelli M; Falco G; Rizzuto A; Viglietto G
    Oncotarget; 2022; 13():755. PubMed ID: 35634243
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correction: Next-generation multimodality of nutrigenomic cancer therapy: sulforaphane in combination with acetazolamide actively target bronchial carcinoid cancer in disabling the PI3K/Akt/mTOR survival pathway and inducing apoptosis.
    Mokhtari RB; Qorri B; Baluch N; Sparaneo A; Fabrizio FP; Muscarella LA; Tyker A; Kumar S; Cheng HM; Szewczuk MR; Das B; Yeger H
    Oncotarget; 2022; 13():968-969. PubMed ID: 36093295
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Correction: Co-targeting the MAPK and PI3K/AKT/mTOR pathways in two genetically engineered mouse models of schwann cell tumors reduces tumor grade and multiplicity.
    Watson AL; Keller BJ; Williams KA; Damle NN; Finnerty SJ; Anderson LK; Greeley AD; Keng VW; Rahrmann EP; Halfond AL; Powell NM; Collins MH; Rizvi T; Moertel CL; Ratner N; Largaespada DA
    Oncotarget; 2020 Sep; 11(39):3618-3620. PubMed ID: 33062197
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Correction:
    Terzo EA; Lim AR; Chytil A; Chiang YC; Farmer L; Gessner KH; Walker CL; Jansen VM; Rathmell WK
    Oncotarget; 2019 Oct; 10(59):6391-6392. PubMed ID: 31695846
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Correction: Combined inhibition of PI3K and Src kinases demonstrates synergistic therapeutic efficacy in clear-cell renal carcinoma.
    Caroline R; Sofia G; Catherine P; Remi B; Pierre C; Olivier B; Laurent G; Valentin A; Claude C; Odile F
    Oncotarget; 2019 Mar; 10(22):2236. PubMed ID: 31040915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Correction: A genetic variant in SLC28A3, rs56350726, is associated with progression to castration-resistant prostate cancer in a Korean population with metastatic prostate cancer.
    Jo JK; Oh JJ; Kim YT; Moon HS; Choi HY; Park S; Ho JN; Yoon S; Park HY; Byun SS
    Oncotarget; 2018 Aug; 9(61):31938. PubMed ID: 30159135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Correction: Cytochrome P450 1B1 inhibition suppresses tumorigenicity of prostate cancer
    Chang I; Mitsui Y; Kim SK; Sun JS; Jeon HS; Kang JY; Kang NJ; Fukuhara S; Gill A; Shahryari V; Tabatabai ZL; Greene KL; Dahiya R; Shin DM; Tanaka Y
    Oncotarget; 2018 Sep; 9(75):34190. PubMed ID: 30344932
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGF promotes neuroendocrine-like differentiation of prostate cancer cells in the presence of LY294002 through increased ErbB2 expression independent of the phosphatidylinositol 3-kinase-AKT pathway.
    Cortés MA; Cariaga-Martinez AE; Lobo MV; Martín Orozco RM; Motiño O; Rodríguez-Ubreva FJ; Angulo J; López-Ruiz P; Colás B
    Carcinogenesis; 2012 Jun; 33(6):1169-77. PubMed ID: 22461520
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Long-term androgen-ablation causes increased resistance to PI3K/Akt pathway inhibition in prostate cancer cells.
    Pfeil K; Eder IE; Putz T; Ramoner R; Culig Z; Ueberall F; Bartsch G; Klocker H
    Prostate; 2004 Feb; 58(3):259-68. PubMed ID: 14743465
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Correction: Establishment of preclinical chemotherapy models for gastroenteropancreatic neuroendocrine carcinoma.
    Ohmoto A; Suzuki M; Takai E; Rokutan H; Fujiwara Y; Morizane C; Yanagihara K; Shibata T; Yachida S
    Oncotarget; 2019 Sep; 10(52):5494. PubMed ID: 31534635
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Correction: Regulation of tumor suppressor EAF2 polyubiquitination by ELL1 and SIAH2 in prostate cancer cells.
    Yu X; Ai J; Cai L; Jing Y; Wang D; Dong J; Pascal LE; Zhang J; Luo R; Wang Z
    Oncotarget; 2019 Dec; 10(67):7181-7182. PubMed ID: 31903175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Correction: The dual PI3K/mTOR inhibitor dactolisib elicits anti-tumor activity
    Shi F; Zhang J; Liu H; Wu L; Jiang H; Wu Q; Liu T; Lou M; Wu H
    Oncotarget; 2018 Mar; 9(24):17255. PubMed ID: 29683149
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Correction: Metabolic syndrome, endocrine disruptors and prostate cancer associations: biochemical and pathophysiological evidences.
    Quagliariello V; Rossetti S; Cavaliere C; Di Palo R; Lamantia E; Castaldo L; Nocerino F; Ametrano G; Cappuccio F; Malzone G; Montanari M; Vanacore D; Romano FJ; Piscitelli R; Iovane G; Pepe MF; Berretta M; D'Aniello C; Perdonà S; Muto P; Botti G; Ciliberto G; Veneziani BM; De Falco F; Maiolino P; Caraglia M; Montella M; Iaffaioli RV; Facchini G
    Oncotarget; 2017 Sep; 8(37):62816. PubMed ID: 28977991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Correction: Upregulation of microRNA135a-3p and death receptor 5 plays a critical role in Tanshinone I sensitized prostate cancer cells to TRAIL induced apoptosis.
    Shin EA; Sohn EJ; Won G; Choi JU; Jeong M; Kim B; Kim MJ; Kim SH
    Oncotarget; 2018 Jul; 9(55):30720. PubMed ID: 30093981
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correction: Overexpression of AKR1C3 significantly enhances human prostate cancer cells resistance to radiation.
    Sun SQ; Gu X; Gao XS; Li Y; Yu H; Xiong W; Yu H; Wang W; Li Y; Teng Y; Zhou D
    Oncotarget; 2020 Apr; 11(17):1575. PubMed ID: 32391126
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.